Joshua Kennedy
Concepts (243)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Asthma | 20 | 2024 | 281 | 5.780 |
Why?
| Picornaviridae Infections | 10 | 2022 | 18 | 3.790 |
Why?
| Rhinovirus | 13 | 2022 | 22 | 3.490 |
Why?
| Virus Diseases | 4 | 2024 | 39 | 2.730 |
Why?
| Rhinitis | 5 | 2018 | 29 | 2.520 |
Why?
| Sinusitis | 5 | 2018 | 50 | 2.440 |
Why?
| Desensitization, Immunologic | 5 | 2018 | 107 | 2.060 |
Why?
| Hypersensitivity | 6 | 2022 | 77 | 1.700 |
Why?
| Lung | 4 | 2024 | 486 | 1.320 |
Why?
| Drug Hypersensitivity | 3 | 2018 | 36 | 1.260 |
Why?
| Respiratory Hypersensitivity | 4 | 2020 | 17 | 1.120 |
Why?
| Respiratory Tract Infections | 3 | 2024 | 75 | 1.080 |
Why?
| Disaccharides | 2 | 2015 | 11 | 0.970 |
Why?
| Immunoglobulin E | 8 | 2020 | 92 | 0.960 |
Why?
| Urticaria | 2 | 2015 | 18 | 0.960 |
Why?
| Rhinitis, Allergic, Perennial | 2 | 2014 | 4 | 0.950 |
Why?
| Androstadienes | 2 | 2014 | 10 | 0.950 |
Why?
| Meat | 2 | 2015 | 55 | 0.950 |
Why?
| Rhinitis, Allergic, Seasonal | 2 | 2014 | 7 | 0.950 |
Why?
| Coinfection | 1 | 2024 | 38 | 0.910 |
Why?
| Respiratory Sounds | 5 | 2022 | 48 | 0.900 |
Why?
| Viruses | 1 | 2023 | 21 | 0.890 |
Why?
| Pharyngitis | 1 | 2022 | 16 | 0.860 |
Why?
| Humans | 46 | 2024 | 49974 | 0.840 |
Why?
| Carbachol | 3 | 2020 | 27 | 0.830 |
Why?
| Streptococcal Infections | 1 | 2022 | 46 | 0.820 |
Why?
| Hospitalization | 2 | 2024 | 652 | 0.790 |
Why?
| Allergens | 6 | 2019 | 139 | 0.700 |
Why?
| Rural Population | 1 | 2024 | 540 | 0.700 |
Why?
| Child | 14 | 2024 | 6847 | 0.690 |
Why?
| Eosinophils | 3 | 2017 | 39 | 0.690 |
Why?
| Th2 Cells | 2 | 2016 | 21 | 0.680 |
Why?
| Bronchoconstriction | 1 | 2019 | 6 | 0.660 |
Why?
| Anaphylaxis | 2 | 2018 | 71 | 0.650 |
Why?
| Aspirin | 2 | 2017 | 114 | 0.640 |
Why?
| Bronchodilator Agents | 2 | 2019 | 73 | 0.630 |
Why?
| Mesalamine | 1 | 2017 | 9 | 0.580 |
Why?
| Ketorolac | 1 | 2016 | 2 | 0.570 |
Why?
| Itraconazole | 1 | 2016 | 40 | 0.560 |
Why?
| Colitis, Ulcerative | 1 | 2017 | 50 | 0.560 |
Why?
| Staphylococcus | 2 | 2013 | 35 | 0.550 |
Why?
| Viral Load | 3 | 2022 | 76 | 0.550 |
Why?
| Food Hypersensitivity | 2 | 2019 | 100 | 0.550 |
Why?
| Acetaminophen | 1 | 2019 | 283 | 0.530 |
Why?
| Immunologic Factors | 1 | 2016 | 114 | 0.520 |
Why?
| Child, Preschool | 8 | 2024 | 3871 | 0.480 |
Why?
| Arkansas | 6 | 2024 | 1977 | 0.470 |
Why?
| Candidiasis | 1 | 2014 | 114 | 0.460 |
Why?
| Allergy and Immunology | 1 | 2013 | 14 | 0.450 |
Why?
| Adolescent | 12 | 2024 | 6356 | 0.440 |
Why?
| Hypersensitivity, Delayed | 1 | 2013 | 21 | 0.440 |
Why?
| Lymphangitis | 1 | 2013 | 2 | 0.440 |
Why?
| Manikins | 1 | 2013 | 35 | 0.440 |
Why?
| Emergency Medicine | 1 | 2013 | 52 | 0.440 |
Why?
| Bronchi | 1 | 2012 | 43 | 0.420 |
Why?
| Pruritus | 1 | 2013 | 44 | 0.420 |
Why?
| Eosinophilia | 1 | 2013 | 37 | 0.420 |
Why?
| Common Cold | 1 | 2012 | 6 | 0.420 |
Why?
| Edema | 1 | 2013 | 67 | 0.410 |
Why?
| Male | 17 | 2024 | 25241 | 0.410 |
Why?
| Chronic Disease | 4 | 2016 | 567 | 0.400 |
Why?
| Enterovirus Infections | 2 | 2022 | 5 | 0.390 |
Why?
| Animals | 11 | 2020 | 13187 | 0.380 |
Why?
| Pediatrics | 1 | 2013 | 279 | 0.360 |
Why?
| Female | 16 | 2024 | 26472 | 0.360 |
Why?
| Staphylococcal Infections | 1 | 2013 | 268 | 0.360 |
Why?
| Emergency Service, Hospital | 2 | 2024 | 486 | 0.330 |
Why?
| Cytokines | 3 | 2024 | 612 | 0.330 |
Why?
| Interferons | 2 | 2022 | 38 | 0.330 |
Why?
| Diagnosis, Differential | 3 | 2018 | 1037 | 0.320 |
Why?
| Anti-Allergic Agents | 2 | 2020 | 15 | 0.320 |
Why?
| Pandemics | 2 | 2024 | 559 | 0.310 |
Why?
| Anti-Bacterial Agents | 1 | 2013 | 744 | 0.300 |
Why?
| Immunity, Innate | 3 | 2024 | 104 | 0.300 |
Why?
| Age Factors | 3 | 2024 | 1087 | 0.300 |
Why?
| Bacteria | 2 | 2023 | 224 | 0.300 |
Why?
| Disease Progression | 3 | 2020 | 825 | 0.270 |
Why?
| Adult | 10 | 2022 | 13236 | 0.260 |
Why?
| Young Adult | 5 | 2022 | 3958 | 0.260 |
Why?
| Interleukins | 2 | 2015 | 32 | 0.240 |
Why?
| Mycoplasma pneumoniae | 1 | 2024 | 4 | 0.240 |
Why?
| Skin Tests | 2 | 2013 | 58 | 0.220 |
Why?
| Swine | 2 | 2015 | 393 | 0.220 |
Why?
| Virus Replication | 1 | 2024 | 140 | 0.220 |
Why?
| Streptococcus pyogenes | 1 | 2022 | 18 | 0.220 |
Why?
| Antiviral Agents | 1 | 2024 | 173 | 0.210 |
Why?
| Middle Aged | 5 | 2019 | 12069 | 0.200 |
Why?
| Autoantibodies | 1 | 2021 | 116 | 0.190 |
Why?
| Infant | 3 | 2024 | 3567 | 0.190 |
Why?
| Enterovirus | 1 | 2020 | 4 | 0.180 |
Why?
| Muscle, Smooth | 1 | 2020 | 63 | 0.180 |
Why?
| Respiratory System | 1 | 2020 | 26 | 0.180 |
Why?
| Calcium Signaling | 1 | 2020 | 56 | 0.180 |
Why?
| Organ Culture Techniques | 1 | 2019 | 48 | 0.160 |
Why?
| Disease Susceptibility | 1 | 2019 | 89 | 0.160 |
Why?
| Mice, Inbred Strains | 1 | 2019 | 161 | 0.160 |
Why?
| Nasal Polyps | 1 | 2018 | 6 | 0.160 |
Why?
| Treatment Outcome | 5 | 2018 | 5141 | 0.160 |
Why?
| Acetazolamide | 1 | 2018 | 19 | 0.160 |
Why?
| Albuterol | 1 | 2019 | 54 | 0.160 |
Why?
| Pseudotumor Cerebri | 1 | 2018 | 24 | 0.160 |
Why?
| RNA, Viral | 2 | 2020 | 125 | 0.150 |
Why?
| Risk Factors | 2 | 2024 | 3613 | 0.150 |
Why?
| Food Supply | 1 | 2019 | 91 | 0.150 |
Why?
| Host-Pathogen Interactions | 1 | 2019 | 134 | 0.150 |
Why?
| Parainfluenza Virus 3, Human | 1 | 2017 | 5 | 0.150 |
Why?
| Respirovirus Infections | 1 | 2017 | 6 | 0.150 |
Why?
| Anticonvulsants | 1 | 2018 | 121 | 0.150 |
Why?
| Immunization | 2 | 2017 | 67 | 0.140 |
Why?
| Prevalence | 2 | 2019 | 944 | 0.140 |
Why?
| Cross-Sectional Studies | 3 | 2022 | 1557 | 0.140 |
Why?
| Eosinophilic Esophagitis | 1 | 2017 | 34 | 0.140 |
Why?
| Th1-Th2 Balance | 1 | 2016 | 2 | 0.140 |
Why?
| Infant, Newborn | 1 | 2024 | 2772 | 0.140 |
Why?
| Leukotrienes | 1 | 2016 | 9 | 0.140 |
Why?
| Health Literacy | 1 | 2019 | 128 | 0.140 |
Why?
| Cells, Cultured | 2 | 2020 | 1573 | 0.140 |
Why?
| Esophagus | 1 | 2017 | 84 | 0.140 |
Why?
| Immunocompromised Host | 1 | 2017 | 119 | 0.140 |
Why?
| Lymphocyte Activation | 1 | 2016 | 172 | 0.130 |
Why?
| Genetic Predisposition to Disease | 1 | 2019 | 510 | 0.130 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 169 | 0.130 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2017 | 121 | 0.130 |
Why?
| Intracellular Membranes | 1 | 1995 | 22 | 0.130 |
Why?
| Dose-Response Relationship, Drug | 1 | 2019 | 1376 | 0.130 |
Why?
| Interleukin-17 | 1 | 2015 | 36 | 0.120 |
Why?
| Basophils | 1 | 2014 | 15 | 0.120 |
Why?
| Candidiasis, Chronic Mucocutaneous | 1 | 2014 | 2 | 0.120 |
Why?
| Myoglobin | 1 | 1995 | 25 | 0.120 |
Why?
| Thymoma | 1 | 2014 | 13 | 0.120 |
Why?
| Eosinophil Cationic Protein | 1 | 2014 | 1 | 0.120 |
Why?
| Nasal Lavage Fluid | 1 | 2014 | 2 | 0.120 |
Why?
| Oxidative Stress | 1 | 2019 | 770 | 0.120 |
Why?
| Candida | 1 | 2014 | 60 | 0.120 |
Why?
| Decision Making, Computer-Assisted | 1 | 2014 | 4 | 0.120 |
Why?
| Leukocyte Count | 1 | 2014 | 70 | 0.120 |
Why?
| Administration, Intranasal | 1 | 2014 | 28 | 0.120 |
Why?
| Superantigens | 1 | 2013 | 1 | 0.120 |
Why?
| Intercellular Adhesion Molecule-1 | 1 | 2014 | 63 | 0.120 |
Why?
| Markov Chains | 1 | 2014 | 30 | 0.120 |
Why?
| Cell Differentiation | 1 | 2016 | 651 | 0.110 |
Why?
| Emergency Treatment | 1 | 2013 | 29 | 0.110 |
Why?
| Nasal Mucosa | 1 | 2013 | 19 | 0.110 |
Why?
| Case-Control Studies | 2 | 2014 | 1131 | 0.110 |
Why?
| Preoperative Period | 1 | 2013 | 46 | 0.110 |
Why?
| Mice, Inbred C57BL | 1 | 2019 | 1816 | 0.110 |
Why?
| Virginia | 1 | 2013 | 17 | 0.110 |
Why?
| Decision Support Techniques | 1 | 2014 | 70 | 0.110 |
Why?
| Antibodies, Anti-Idiotypic | 1 | 2013 | 19 | 0.110 |
Why?
| Cats | 1 | 2013 | 79 | 0.110 |
Why?
| Paranasal Sinuses | 1 | 2013 | 18 | 0.110 |
Why?
| Angioedema | 1 | 2013 | 9 | 0.110 |
Why?
| Cough | 1 | 2013 | 54 | 0.110 |
Why?
| Affect | 1 | 2013 | 99 | 0.110 |
Why?
| Dogs | 1 | 2013 | 182 | 0.110 |
Why?
| Postoperative Period | 1 | 2013 | 170 | 0.110 |
Why?
| Acute Disease | 1 | 2014 | 366 | 0.110 |
Why?
| Sex Distribution | 1 | 2013 | 134 | 0.110 |
Why?
| Age Distribution | 1 | 2013 | 168 | 0.110 |
Why?
| Statistics, Nonparametric | 1 | 2013 | 194 | 0.110 |
Why?
| Cattle | 1 | 2013 | 210 | 0.110 |
Why?
| Polymerase Chain Reaction | 1 | 2014 | 453 | 0.110 |
Why?
| Equipment Design | 1 | 2013 | 284 | 0.110 |
Why?
| Cost-Benefit Analysis | 1 | 2014 | 274 | 0.110 |
Why?
| Pyroglyphidae | 1 | 2012 | 1 | 0.100 |
Why?
| Seroepidemiologic Studies | 2 | 2022 | 43 | 0.100 |
Why?
| Odds Ratio | 1 | 2014 | 545 | 0.100 |
Why?
| Oxygen | 1 | 1995 | 326 | 0.100 |
Why?
| Myocardium | 1 | 1995 | 436 | 0.100 |
Why?
| Antibodies, Viral | 2 | 2022 | 88 | 0.100 |
Why?
| Biofilms | 1 | 2013 | 181 | 0.100 |
Why?
| Patient Care Team | 1 | 2013 | 254 | 0.100 |
Why?
| Virulence | 1 | 2012 | 173 | 0.100 |
Why?
| Prospective Studies | 2 | 2017 | 2364 | 0.100 |
Why?
| Chemokine CXCL10 | 2 | 2022 | 19 | 0.100 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2013 | 225 | 0.100 |
Why?
| Logistic Models | 1 | 2014 | 888 | 0.100 |
Why?
| Clinical Competence | 1 | 2013 | 393 | 0.090 |
Why?
| Incidence | 1 | 2013 | 1003 | 0.090 |
Why?
| Time Factors | 2 | 2013 | 2903 | 0.080 |
Why?
| Tomography, X-Ray Computed | 1 | 2014 | 1159 | 0.080 |
Why?
| Cohort Studies | 1 | 2013 | 1422 | 0.080 |
Why?
| Risk Assessment | 1 | 2013 | 1259 | 0.080 |
Why?
| Genome, Viral | 2 | 2020 | 79 | 0.080 |
Why?
| Prognosis | 1 | 2013 | 1942 | 0.080 |
Why?
| United States | 1 | 2016 | 4860 | 0.070 |
Why?
| Respiratory Function Tests | 2 | 2020 | 90 | 0.060 |
Why?
| Interleukin-15 | 1 | 2022 | 16 | 0.050 |
Why?
| Serologic Tests | 1 | 2022 | 26 | 0.050 |
Why?
| Multiple Myeloma | 1 | 2017 | 2929 | 0.050 |
Why?
| Epidermal Growth Factor | 1 | 2022 | 34 | 0.050 |
Why?
| Granulocyte Colony-Stimulating Factor | 1 | 2022 | 61 | 0.050 |
Why?
| Interleukin-8 | 1 | 2022 | 87 | 0.050 |
Why?
| Cluster Analysis | 1 | 2022 | 235 | 0.050 |
Why?
| Peptidyl-Dipeptidase A | 1 | 2021 | 27 | 0.050 |
Why?
| Receptor, Angiotensin, Type 1 | 1 | 2021 | 57 | 0.050 |
Why?
| Renin-Angiotensin System | 1 | 2021 | 58 | 0.050 |
Why?
| Interleukin-6 | 1 | 2022 | 264 | 0.050 |
Why?
| Myosin Light Chains | 1 | 2020 | 5 | 0.050 |
Why?
| Angiotensin II | 1 | 2021 | 157 | 0.050 |
Why?
| Placebo Effect | 1 | 2020 | 17 | 0.040 |
Why?
| Histamine | 1 | 2020 | 25 | 0.040 |
Why?
| Primary Prevention | 1 | 2020 | 44 | 0.040 |
Why?
| Myocytes, Smooth Muscle | 1 | 2020 | 86 | 0.040 |
Why?
| Muscle Contraction | 1 | 2020 | 105 | 0.040 |
Why?
| Inflammation Mediators | 1 | 2020 | 112 | 0.040 |
Why?
| Tertiary Healthcare | 1 | 2019 | 16 | 0.040 |
Why?
| Protein Processing, Post-Translational | 1 | 2020 | 171 | 0.040 |
Why?
| Hypersensitivity, Immediate | 1 | 2018 | 11 | 0.040 |
Why?
| Phosphorylation | 1 | 2020 | 535 | 0.040 |
Why?
| Coculture Techniques | 1 | 2018 | 146 | 0.040 |
Why?
| Air Pollutants | 1 | 2018 | 60 | 0.040 |
Why?
| Double-Blind Method | 1 | 2020 | 681 | 0.040 |
Why?
| Immune Tolerance | 1 | 2018 | 96 | 0.040 |
Why?
| Particulate Matter | 1 | 2017 | 52 | 0.040 |
Why?
| Seasons | 1 | 2017 | 81 | 0.040 |
Why?
| Proton Pump Inhibitors | 1 | 2017 | 84 | 0.030 |
Why?
| Cross Infection | 1 | 2017 | 95 | 0.030 |
Why?
| Environmental Exposure | 1 | 2017 | 199 | 0.030 |
Why?
| Partial Pressure | 1 | 1995 | 14 | 0.030 |
Why?
| Phosphorus | 1 | 1995 | 27 | 0.030 |
Why?
| Longitudinal Studies | 1 | 2017 | 688 | 0.030 |
Why?
| Receptors, Cytokine | 1 | 2014 | 11 | 0.030 |
Why?
| Protons | 1 | 1995 | 69 | 0.030 |
Why?
| Magnetic Resonance Spectroscopy | 1 | 1995 | 244 | 0.030 |
Why?
| Protein-Tyrosine Kinases | 1 | 2014 | 95 | 0.030 |
Why?
| Adenosine Triphosphate | 1 | 1995 | 233 | 0.030 |
Why?
| Intracellular Signaling Peptides and Proteins | 1 | 2014 | 142 | 0.030 |
Why?
| Quality of Life | 1 | 2019 | 836 | 0.030 |
Why?
| Exhalation | 1 | 2012 | 17 | 0.030 |
Why?
| Epitopes | 1 | 2012 | 59 | 0.030 |
Why?
| Risk | 1 | 2012 | 320 | 0.020 |
Why?
| Rats, Sprague-Dawley | 1 | 1995 | 1597 | 0.020 |
Why?
| Nitric Oxide | 1 | 2012 | 253 | 0.020 |
Why?
| Spirometry | 1 | 2008 | 29 | 0.020 |
Why?
| Rats | 1 | 1995 | 3305 | 0.020 |
Why?
| Respiratory Therapy | 1 | 2008 | 34 | 0.020 |
Why?
| Adrenal Cortex Hormones | 1 | 2008 | 94 | 0.020 |
Why?
| Administration, Oral | 1 | 2008 | 426 | 0.020 |
Why?
| Practice Guidelines as Topic | 1 | 2008 | 449 | 0.020 |
Why?
| Severity of Illness Index | 1 | 2008 | 945 | 0.020 |
Why?
| Retrospective Studies | 1 | 2017 | 6108 | 0.020 |
Why?
| Follow-Up Studies | 1 | 2008 | 2182 | 0.010 |
Why?
|
|
Kennedy's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|